 |
59 Diseases |  |
24 Trials |
|
24 Trials |  |
1999 News |  |
| «12...1011121314151617181920...2526» |
- | carbamazepine / Generic mfg.
Journal: Factors correlated with intracranial interictal epileptiform discharges in refractory epilepsy. (Pubmed Central) - Apr 20, 2021
The current study ranks the relative influence that subject-specific factors have on IED rates and highlights the importance of considering certain factors, such as SOZ location and ASM status, when analyzing IEDs for clinical or research purposes.
- | Trileptal (oxcarbazepine) / Novartis
Journal: Potential induction of epileptic spasms by nonselective voltage-gated sodium channel blockade: Interaction with etiology. (Pubmed Central) - Apr 20, 2021
This study suggests that voltage-gated sodium channel blockade may induce epileptic spasms among children at risk on the basis of etiology. Further study is warranted to replicate these findings, ascertain possible drug- and dose-specific risks, and identify potential mechanisms of harm.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Lacosamide and myoclonic seizures: what is the risk of aggravation? (Pubmed Central) - Apr 20, 2021
Further study is warranted to replicate these findings, ascertain possible drug- and dose-specific risks, and identify potential mechanisms of harm. No abstract available
- | carbamazepine / Generic mfg.
Journal: Identification of seizure clusters using free text notes in an electronic seizure diary. (Pubmed Central) - Apr 15, 2021
Free text notes captured information about SC not available from the structured diary data. Diary FTN contain information of high importance to people with epilepsy, written in their own words.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo, Fycompa (perampanel) / Eisai
[VIRTUAL] Cost-Effectiveness and Budget Impact of Perampanel Versus Lacosamide As Adjunctive Treatment for Patients with Partial-Onset Seizures in China () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1082;
P3
This study indicates that PER as adjunctive treatment brings value to patients with partial-onset seizures in China. The cost-effectiveness of PER is dominant to its peer and the incremental budget is within affordability of Chinese payers.
- Xcopri (cenobamate) / SK Bio, Arvelle Therap
[VIRTUAL] The Budget Impact of Cenobamate for the Treatment of Uncontrolled Focal Epilepsy () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1076;
The nominal increase in pharmacy spend was balanced by a reduction in healthcare utilization costs, mostly due to fewer inpatient hospitalizations. Supported by SK Life Science, Inc.
- carbamazepine / Generic mfg.
[VIRTUAL] IMPACT of LONG-TERM Drug Monotherapy of Enzyme Inducing Drugs on SERUM Lipid Concentrations in Patients with Epilepsy- Implications to Ischemic Heart Disease () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_884;
The increase in the TC, TG, LDL-C, VLDL-C levels maybe associated with the liver enzyme induction. Carbamazepine & Oxcarbazepine exclusively increases the parameters to highly significant values whereas the non inducers did not show any increase.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Review, Journal: Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy? (Pubmed Central) - Apr 10, 2021
More evidence is currently needed on lacosamide pharmacokinetics in pregnancy and critical illness. While it is not practical to utilize TDM for all patients, TDM may be useful in patients taking enzyme-inducer AEDs, in patients with decreased renal function or on dialysis, and older adults.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Review, Journal: The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. (Pubmed Central) - Apr 10, 2021
Several factors including mechanism of co-administration of ASMs and personal history of psychiatric disorder should be considered as important in the development of cognitive and psychiatric side effects. However, the heterogeneity between studies make the quality of evidence weaker and further trials are needed.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: A multimodal diagnostic approach for lateralised rhythmic delta activity in the ictal-interictal continuum. (Pubmed Central) - Apr 7, 2021
In the literature, a correlation between metabolic/perfusion imaging and ictal-interictal continuum patterns is described regarding lateralised periodic discharges but less studied for LRDA. In this case, we adopted a multimodal approach, integrating advanced imaging, EEG, clinical features, and response to therapy, to consider the overall clinical presentation as focal NCSE.
- | lorazepam / Generic mfg., midazolam hydrochloride / Generic mfg.
Journal: Treatment of Status Epilepticus: What Are the Guidelines and Are We Following Them? (Pubmed Central) - Apr 7, 2021
This retrospective review demonstrates how guidelines and recommendations for SE are not consistently followed. Under dosing of AEDs and aggressive weaning of anesthetic agents may result in higher morbidity and mortality.
- | lorazepam / Generic mfg., midazolam hydrochloride / Generic mfg.
Journal: Diagnosing Status Epilepticus (Pubmed Central) - Apr 1, 2021
Abnormal cEEG findings during status epilepticus vary from rhythmic delta activity and epileptiform and generalized periodic discharges to ictal discharges. Accurate diagnosis of status epilepticus using MRI and cEEG can offer earlier intervention, such as prompt administration of benzodiazepines, midazolam, lorazepam, ultimately resulting in a good recovery.
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Mar 25, 2021
P2, N=5, Terminated, Sponsor: Duke University
Accurate diagnosis of status epilepticus using MRI and cEEG can offer earlier intervention, such as prompt administration of benzodiazepines, midazolam, lorazepam, ultimately resulting in a good recovery. N=232 --> 5 | Trial completion date: Jan 2023 --> Feb 2021 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Dec 2020; Did not enroll as planned
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. (Pubmed Central) - Mar 23, 2021
P3
N=232 --> 5 | Trial completion date: Jan 2023 --> Feb 2021 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Dec 2020; Did not enroll as planned Lacosamide was efficacious and generally safe as adjunctive treatment for uncontrolled PGTCS in patients with IGE.
- || Trileptal (oxcarbazepine) / Novartis
Clinical, Journal: Trends in prescribing patterns of antiepileptic drugs among older adult inpatients in a Brazilian tertiary center. (Pubmed Central) - Mar 23, 2021
Phenytoin was the main suboptimal AED prescribed in our population, and convulsive SE and acute symptomatic seizures associated with some etiologies were independent risk factors for phenytoin prescription. These results suggest ongoing commitment to reducing the prescription of suboptimal AEDs, particularly phenytoin in Brazilian emergence rooms.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal, Real-world evidence: Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience. (Pubmed Central) - Mar 20, 2021
The mechanism was postulated to be the sodium channel inhibiting action of LCM. Our study has shown LCM to have comparable efficacy and tolerability in post-marketing experience when compared with the landmark randomized controlled trials.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Eastern Equine Encephalitis in a Patient with Chronic Neutropenia Secondary to T-Cell Large Granular Lymphocytic Leukemia () - Mar 18, 2021 - Abstract #AAN2021AAN_1757;
Our study has shown LCM to have comparable efficacy and tolerability in post-marketing experience when compared with the landmark randomized controlled trials. Recognizing the early imaging findings of EEE can assist with timely diagnosis and treatment.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] A case of Delayed and Reversible Chemotherapy-Induced Leukoencephalopathy () - Mar 18, 2021 - Abstract #AAN2021AAN_969;
Chemotherapy-induced leukoencephalopathy is a potentially reversible phenomenon. To the best of our knowledge, this is the first case of delayed leukoencephalopathy secondary to chemotherapy to be reported, with remarkable clinical and radiological resolution with steroids.
- lorazepam / Generic mfg., midazolam hydrochloride / Generic mfg.
[VIRTUAL] Pediatric Phencyclidine (PCP) Intoxication: First Reported Human MRI and EEG Findings () - Mar 18, 2021 - Abstract #AAN2021AAN_904;
The patient’s EEG and late MRI findings are analogous to animal models of PCP intoxication, including high voltage frontally predominant delta waves, and global volume loss. Early diffusion restriction and T2 hyperintensity in white matter seen in our patient are unique findings not previously described.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo, Briviact (brivaracetam) / UCB
[VIRTUAL] Intravenous Antiseizure Medication Utilization Patterns Among Seizure Patients Treated in US Hospitals: a Database Analysis () - Mar 18, 2021 - Abstract #AAN2021AAN_896;
A high percentage of patients receiving IV ASMs with no step-down to oral was observed, which may signal inappropriate post-discharge treatment. More research is needed to better understand why many IV ASMs were not stepped-down to an oral ASM prior to discharge.
- Xcopri (cenobamate) / SK Bio, Arvelle Therap
[VIRTUAL] Clinical Update For Cenobamate: Patients’ Experiences of Efficacy and Side Effects () - Mar 18, 2021 - Abstract #AAN2021AAN_878;
Adverse effects represent Cenobamate’s pharmacokinetic/pharmacodynamic interactions with other AEDs. To remedy this, it may be reasonable to proactively reduce doses of concurrent AEDs, when safe from clinical standpoint.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Transition from Intravenous to Enteral Administration of Levetiracetam and Lacosamide in the Hospital Setting: Preliminary Data () - Mar 18, 2021 - Abstract #AAN2021AAN_876;
This preliminary data shows that IV and ET therapeutic levels are comparable suggesting that ET is as effective as IV in the hospital setting. There is also potential drug cost saving when transitioning from IV to ET.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Levetiracetam and Lacosamide in the treatment of Non-Convulsive Status Epilepticus () - Mar 18, 2021 - Abstract #AAN2021AAN_868;
While, levetiracetam was found to be more effective as a third line agent or later. Our study provides evidence for lacosamide to be a future therapeutic option in the treatment of NCSE in comparison to a well-known control, levetiracetam.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Alternating Seizure Focus In Mitochondrial Disease () - Mar 18, 2021 - Abstract #AAN2021AAN_834;
Migrating imaging lesions are a known feature of MELAS commonly caused by the A3243G mutation. The prognosis of epilepsy in mitochondrial disease is poor.
- Xcopri (cenobamate) / SK Bio, Arvelle Therap
[VIRTUAL] Long-Term Efficacy of Cenobamate by Concomitant Antiseizure Medication: Post-hoc Analysis of the C017 Open-label Extension Study () - Mar 18, 2021 - Abstract #AAN2021AAN_787;
The prognosis of epilepsy in mitochondrial disease is poor. Adjunctive treatment with cenobamate was associated with sustained long-term efficacy in patients taking regimens including levetiracetam, lamotrigine, or lacosamide at the beginning of the OLE.
- Xcopri (cenobamate) / SK Bio, Arvelle Therap
[VIRTUAL] Efficacy of Cenobamate by Concomitant Antiseizure Medications in Patients With Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study () - Mar 18, 2021 - Abstract #AAN2021AAN_776;
Baseline ASM use was generally consistent among patients continuing cenobamate, discontinuing cenobamate, and achieving 100% seizure reduction ≥12 months. The AEs associated with the combinations were consistent with the known profiles of these ASMs.
- Xcopri (cenobamate) / SK Bio, Arvelle Therap, Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Dose Adjustments to Concomitant Antiseizure Medications: Post-hoc Analysis of a Phase 3, Open-Label Study of Cenobamate for Treatment of Uncontrolled Focal Seizures () - Mar 18, 2021 - Abstract #AAN2021AAN_768;
In this post-hoc analysis, reducing doses of concomitant ASMs, across a range of drugs with various mechanisms of action, led to fewer cenobamate discontinuations. Decreasing doses of phenytoin, clobazam, and lacosamide occurred early compared to most other ASMs.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Review, Journal: The impact of lacosamide on mood disorders in adult patients with epilepsy: A systematic review. (Pubmed Central) - Mar 17, 2021
Even though presently, a negative effect on mood seems unlikely, whether lacosamide could exert a beneficial impact on mood remains controversial. Multicenter, randomized, controlled, double-blind studies are needed to assess the impact on lacosamide on mood disorders, given the low evidence level (Class III and IV) of currently available studies.
- ||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Vimpat causes Psychosis and Complex Partial Seizures and has a risk of Suicide and violence and should be banned by the FDA along with Keppra! UCB Pharmaceuticals should not be making Anti Epilepsy Drugs. Do not let your friends friends kids take these so called medications. 🚫 (Twitter) - Mar 16, 2021
- ||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Vimpat causes Psychosis and Complex Partial Seizures and has a risk of Suicide and violence and should be banned by the FDA along with Keppra! UCB Pharmaceuticals should not be making Anti Epilepsy Drugs. Do not let your friends friends kids take these so called medications. 🚫 (Twitter) - Mar 16, 2021
- ||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Vimpat causes Psychosis and Complex Partial Seizures and has a risk of Suicide and violence and should be banned by the FDA along with Keppra! UCB Pharmaceuticals should not be making Anti Epilepsy Drugs. Do not let your friends friends kids take these so called medications. 🚫 (Twitter) - Mar 16, 2021
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, P4 data, Journal: Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East. (Pubmed Central) - Mar 13, 2021
Multicenter, randomized, controlled, double-blind studies are needed to assess the impact on lacosamide on mood disorders, given the low evidence level (Class III and IV) of currently available studies. LCM is efficacious and overall well tolerated in children with focal-onset seizures and exhibits higher efficacy with early introduction and when added to a non-sodium channel blocker.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Nonconvulsive Status Epilepticus Associated with Theophylline: A Case Report (Pubmed Central) - Mar 9, 2021
However, she developed severe tonic-clonic seizures with right sensory aphasia and right hemiplegia, for which an increased dose of lacosamide was added...We suspect that cerebral infarction may have aggravated the central nervous system damage caused by theophylline, thereby resulting in aminophylline-related non-convulsive status epilepticus. (Received 20 July 2020; Accepted 27 October 2020; Published 1 March 2021).
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Preclinical, Journal: Anticonvulsant Effects of Topiramate and Lacosamide on Pilocarpine-Induced Status Epilepticus in Rats: A Role of Reactive Oxygen Species and Inflammation. (Pubmed Central) - Mar 7, 2021
The two AEDs, in both doses applied, also normalized the CAT activity and MDA levels to control values. In conclusion, we suggest that the antioxidant effect of TPM and LCM might contribute to their anticonvulsant effect against pilocarpine-induced SE, whereas their weak anti-inflammatory effect in the hippocampus is a consequence of reduced SE severity.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Diagnosis and Treatment of Status Epilepticus. (Pubmed Central) - Mar 5, 2021
Use of ketamine, megadose phenobarbital therapy, and multiple combinations of various AEDs including high doses of oral AEDs can also be considered...AEDs alone are poorly effective in the treatment of SE in autoimmune encephalitis. Immunotherapy such as steroids, immunoglobulin, rituximab, or tocilizumab can be effective.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Effects of lacosamide and carbamazepine on lipids in a randomized trial. (Pubmed Central) - Mar 4, 2021
This study provides Class II evidence that CBZ elevates serum lipids, whereas LCM has no effect on lipids. It supports LCM as an appropriate choice for new-onset focal epilepsy.
- || Trileptal (oxcarbazepine) / Novartis
Clinical, Review, Journal: Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention. (Pubmed Central) - Mar 2, 2021
The ASMs that yielded the most data (3 or more studies) were topiramate (TPM), followed by tiagabine (TGB), brivaracetam (BRV), and lamotrigine (LTG)...Promising results, but with data from only one or two studies, were seen with cenobamate (18-59% efficacy above placebo), lacosamide (45.1-78.7%), levetiracetam (40.1-60.3%), oxcarbazepine (58.5-81.5%), and gabapentin (50-53.8%)...This review was our attempt at filling a gap in the literature and calling for universal reporting of data specific to BTC seizure reduction in all future studies, preferably including specific reporting on nocturnal BTCS. This will help enable rational ASM selection to minimize BTC seizures and thereby decrease the risk of SUDEP.
- | carbamazepine / Generic mfg.
Journal: Status epilepticus from GABAR antibody positive encephalitis due to de novo mixed small cell and adenocarcinoma of the prostate. (Pubmed Central) - Feb 27, 2021
He progressed to status epilepticus, which required intravenous immunoglobulin and steroids, followed by plasma exchange 1 week later. The status epilepticus was refractory and required multiple admissions to the intensive care unit.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Safety of Intravenous Push Lacosamide Compared With Intravenous Piggyback at a Tertiary Academic Medical Center. (Pubmed Central) - Feb 25, 2021
Conclusion and Relevance: IVP lacosamide was associated with a similar incidence of cardiovascular, neurological, and infusion site-related adverse events compared with IVPB, in which nearly every adverse event was deemed clinically insignificant. Lacosamide administered via IVP may be considered a safe alternative method of administration in the acute care setting.
- || carbamazepine / Generic mfg.
Clinical, Journal: Contraception in epileptic women (Pubmed Central) - Feb 23, 2021
Family planning counseling at the first visit has been shown to influence the choice of the contraceptive method and the early initiation of folic acid in the search for fertility. In conclusion, the different therapeutic options should be analyzed together with the epileptic patients in order to achieve and optimize the best goal for each one.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] A MASQUERADING ECG: LACOSAMIDE ASSOCIATED ECG CHANGES MIMICKING AN INFERIOR STEMI (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_6451;
With lacosamide therapy in the setting of other metabolic stressors, a variety of ECG changes including ST elevations, widened QRS and sinus node dysfunction with AIVR can be observed. This case highlights lacosamide can be associated with ST elevations that mimic STEMI.
- | Briviact (brivaracetam) / UCB
Journal: Intravenous brivaracetam for the management of refractory focal non-convulsive status epilepticus. (Pubmed Central) - Feb 17, 2021
However, limited data exist on brivaracetam's efficacy in SE. We describe a patient case with focal NCSE refractory to levetiracetam, fosphenytoin, lacosamide and valproate who demonstrated clinical and electrographic improvement on continuous electroencephalography monitoring after brivaracetam administration.
- | Trileptal (oxcarbazepine) / Novartis
Journal, Monotherapy: Evidence-based Anti-seizure Monotherapy in Newly Diagnosed Epilepsy: a New Approach. (Pubmed Central) - Feb 9, 2021
Lamotrigine and levetiracetam can be used as first choice for focal seizures and generalized epilepsy with GTC, suitable in all age-groups and for both men and women. Recommendations for GTC seizures have lower evidence than those for focal seizures.
- |||||| lacosamide / Generic mfg.
New trial, HEOR, Real-world evidence, Real-world: A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy (clinicaltrials.gov) - Feb 4, 2021
P, N=200, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| Journal, Adverse events, Combination therapy: Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. (Pubmed Central) - Jan 26, 2021
This study identified two AED combinations that increased the SJS signals and seven combinations that increased the TEN signals. Although AED monotherapies require attention for SJS and TEN, some AED combinations require extra caution.
- ||| lacosamide / Generic mfg.
Enrollment status: A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment (clinicaltrials.gov) - Jan 26, 2021
P3, N=100, Enrolling by invitation, Sponsor: UCB Biopharma SRL
Although AED monotherapies require attention for SJS and TEN, some AED combinations require extra caution. Recruiting --> Enrolling by invitation
- | carbamazepine / Generic mfg.
Journal: What has been the impact of new drug treatments on epilepsy? (Pubmed Central) - Jan 23, 2021
Recruiting --> Enrolling by invitation Although the newer generation ASMs may not have improved the overall seizure control they have advantages in terms of drug-drug interactions and teratogenicity, and thus offer valuable individualized options in the treatment of epilepsy.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Lacosamide-induced recurrent ventricular fibrillation: A case report. (Pubmed Central) - Jan 21, 2021
Only few cases of lacosamide-induced cardiac dysrhythmia have been published. We report a case of several episodes of a life-threatening ventricular fibrillation requiring cardioversion following the first doses of lacosamide as adjunctive epilepsy treatment.
- |||| lacosamide / Generic mfg.
Enrollment open: A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment (clinicaltrials.gov) - Jan 12, 2021
P3, N=100, Recruiting, Sponsor: UCB Biopharma SRL
We report a case of several episodes of a life-threatening ventricular fibrillation requiring cardioversion following the first doses of lacosamide as adjunctive epilepsy treatment. Not yet recruiting --> Recruiting
- | lacosamide / Generic mfg., duloxetine / Generic mfg.
New P2 trial, Head-to-Head: A Randomized, open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy (EUDRACT) - Jan 12, 2021
P2, N=100, Ongoing, Sponsor: Leiden University Medical Center